Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR26058200.fastq.gz | Fastqsanger.gz | |||
| SRR26058201.fastq.gz | Fastqsanger.gz | |||
| SRR26058202.fastq.gz | Fastqsanger.gz | |||
| SRR26058203.fastq.gz | Fastqsanger.gz | |||
| SRR26058204.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 67 |
Similar Datasets
Project description:This SuperSeries is composed of the following subset Series: GSE41751: Correlated alterations in genome organization, histone methylation, and DNA-lamina interactions in Hutchinson-Gilford progeria syndrome (expression) GSE41757: Correlated alterations in genome organization, histone methylation, and DNA-lamina interactions in Hutchinson-Gilford progeria syndrome (ChIP-seq) GSE41763: Correlated alterations in genome organization, histone methylation, and DNA-lamina interactions in Hutchinson-Gilford progeria syndrome (Hi-C) Refer to individual Series
2012-10-30 | E-GEOD-41764 | biostudies-arrayexpress
Project description:Cockayne syndrome is an inherited premature aging syndrome associated with developmental and neurological disorders. Mutations in the genomic locus encoding CSB are associated with 80% Cockayne syndrome cases. CSB is invovled in relieving UV-induced and oxidative stree. To gain more insights into the fucntion of CSB under these stress, we use ChIP-seq to determine the genomic localization of CSB 1 hour after UV irradiation and menadione treatment. Genomic localization of CSB and remodeling deficient CSBâN1
2015-11-09 | E-GEOD-50925 | biostudies-arrayexpress
Project description:Cockayne syndrome is an inherited premature aging syndrome associated with developmental and neurological disorders. Mutations in the genomic locus encoding CSB are associated with 80% Cockayne syndrome cases. Transcription profiling assays reveal the association of mis-regulation of gene expression with Cockayne syndrome, highlighting the importance of CSB in transcription regulation. However, many questions remain unanswered as how CSB regulates transcription. In this study, we dissect the mechanisms by which CSB regulates transcription during normal growth. By anti-CSB chromatin immunoprecipitation followed by deep sequencing, we found CSB is enriched at genomic regions containing TGASTCA motifs, to which the immediate early gene product C-Jun binds specifically. We further demonstrate that c-Jun co-immunoprecipitates with CSB. In addition, the targeting of CSB to genomic region containing TGASTCA motifs was drastically reduced in cells treated c-Jun shRNA. Reverse transcription followed by quantitative PCR indicates that CSB can regulate gene expression nearby its binding sites, both in activation and repression. The remodeling defective CSBM-bM-^HM-^FN1 mutant is also targeted to TGASTCA motifs, but cannot always substitute CSB function in transcription regulating, suggesting the importance of remodeling by CSB in transcription regulation. Notably, the Cockayne syndrome related mutation encoding protein CSBR670W, which is defective in ATP hydrolysis but is targeted to TGASTCA motifs efficiently, indicating that ATP hydrolysis is dispensable for c-Jun mediated CSB targeting, in sharp contrast to the ATP-dependent targeting mechanism by which CSB is relocated to DNA lesion stalled transcription. Together, these results reveal a second CSB targeting mechanism in which DNA sequence specific transcription factor c-Jun targets CSB to specific genomic region and regulate gene expression. Genomic localization of CSB and remodeling deficient CSBM-bM-^HM-^FN1
2014-03-06 | E-GEOD-50171 | biostudies-arrayexpress
Project description:Turner syndrome is a relatively rare condition that is usually associated with the loss of all or part of an X chromosome. Amniotic fluid is a complicated biological material, could contribute to the understanding of turner syndrome pathogenesis. In this study, ATAC-seq analysis of Turner syndrome (45X) and Female (46XX) amniotic fluid cells was applied to illustrate that genome wide chromatin accessible landscapes. Our results show that Turner Syndrome has higher chromatin accessibility than Female on autosomes and has lower chromosome accessibility on the X chromosome. We identified candidate genomic regions and transcript factors that may play an important role in Turner syndrome pathogenesis. Our analysis suggests that the phenotype of Turner Syndrome should be the result of abnormal regulation of gene expression in the whole genome, not just the result of insufficient doses of X chromosome haploids.
2021-07-01 | GSE154598 | GEO
Project description:Sex chromosomal abnormalities areare associated with multiple defects. In this study, we retrospectively analyzed the single nucleotide polymorphism (SNP) arrays of 186 early embryos with sex chromosomal abnormalities. using single nucleotide polymorphism (SNP) array. Among them, 52 cases of Turner syndrome, 21 cases of triple X syndrome, 35 cases of Klinefelter syndrome and 14 cases of XYY syndrome were detected. Moreover, 27 cases of mosaic sex chromosomal abnormalities were determined. Sex chromosomal deletions and duplications were found in 37 cases. Overall, our results presented a detailed manifestation of sex chromosomal abnormalities.
2022-07-29 | GSE208389 | GEO
Project description:Cockayne syndrome is an inherited premature aging syndrome associated with developmental and neurological disorders. Mutations in the genomic locus encoding CSB are associated with 80% Cockayne syndrome cases. CSB is invovled in relieving UV-induced and oxidative stree. To gain more insights into the fucntion of CSB under these stress, we use ChIP-seq to determine the genomic localization of CSB 1 hour after UV irradiation and menadione treatment.
2015-11-09 | GSE50925 | GEO
Project description:Comparison between miRNA expression in plasma of women with and without metabolic syndrome. We used microarrays to compare the composition of miRNAs in plasma of participants with and without metabolic syndrome (ATP III criteria).
2023-10-02 | GSE239866 | GEO
Project description:Potocki-Shaffer syndrome (PSS) is a rare contiguous gene deletion syndrome marked by haploinsufficiency of genes in chromosomal region 11p11.2p12. Approximately 50 cases of PSS have been reported; however, a syndrome with a PSS-like clinical phenotype caused by 11p11.12p12 duplication has not yet been reported. We first report the 11p11.12p12 duplication in a family with intellectual disability and craniofacial anomalies. 11p11.12p12 duplication syndrome was identified by karyotype analysis. Next-generation sequencing (NGS) analysis clarified the location of the chromosomal variations, which was confirmed by chromosome microarray analysis (CMA). Whole-exome sequencing (WES) was performed to exclude single nucleotide variations (SNVs). The raw data of NGS analysis and WES have been submitted to SRA, the accession number is PRJNA713823.
2021-03-24 | GSE169469 | GEO
Project description:ett Syndrome is a neurological disorder caused by mutation in the MeCP2 gene encoding protein, which is a component of chromatin. The neurological spectrum of Rett Syndrome suggests that this protein plays an important role in the nervous system. Limitations of in vivo studies such as the accumulation of indirect effects have impeded understanding of direct consequences of the loss of MeCP2. Thus, it is important to develop simplified models of Rett Syndrome to create the disease in a dish. This can be achieved for instance by differentiating human neuronal progenitors, which carry various MeCP2 mutations, into a homogeneous neuronal population and analyze alterations in the chromatin states such as methylation, hydroxymethylation, histone modifications and changes in transcription. Protocol: LUHMES cell line of human neural progenitors was differentiated into neurons for 9 days in presence of defined medium. At the end of differentiation, neuronal genomic DNA was extracted using Qiagen DNeasy kit and bisulfite-treated. Adaptors were ligated to purified DNA and captured on an Illumina flow cell for cluster generation. Libraries were sequenced on the Genome Analyzer following the manufacturer's protocols. Sequencing was performed at the Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
2013-01-31 | E-ERAD-112 | biostudies-arrayexpress
Project description:Patients with Cushing’s syndrome (Cushing's syndrome) in remission show sustained fatigue, myopathy, and an increased prevalence of sarcopenia. The mechanisms that determine these persistent muscle problems are not well known. We aimed to identify circulating microRNAs (miRNAs) with differential expression that could be potential biomarkers for the diagnosis and/or prognosis in Cushing's syndrome. In this data set, we analized thirty-six women in sustained remission for 13 ± 7 years (mean ± SD) from Cushing's syndrome, with a median age (IQ range) of 51 (45.2–60) years and mean ± SD BMI of 27 ± 4 Kg/m2, and 36 matched healthy controls using small RNA-sequencing of small RNA purified from plasma samples of these patients and control. In 7 patients sarcopenia was present according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria. Validation was carried out using RT-qPCR. For the validation, Taqman probes were performed on QuantStudio 5 equipment (Applied Biosystems). In a first discovery group using RNA-sequencing, plasma samples of 18 Cushing's syndrome patients and 18 healthy subjects were investigated; circulating miR-28-5p, miR-495-3p and miR-654-5p were upregulated in Cushing's syndrome patients as compared with controls (p<0.05). In a validation study of the 3 upregulated miRNAs in 36 patients and 26 controls, no differences were observed by RT-qPCR; however, the expression of circulating miR-28-5p was upregulated in Cushing's syndrome patients with sarcopenia as compared with those without (AUC for fold-change in the ROC analysis, 0.798; p=0.0156). The optimized cut-off value for miR-28-5p to identify Cushing's syndrome patients with sarcopenia was 3.80, which yielded a sensitivity of 86% and a specificity of 69%.
2024-07-07 | GSE271649 | GEO